Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy

We hereby report a case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy (CSC). Issues regarding safety and adverse effects of bevacizumab are discussed. To the best of our knowledge, this is the first reported case of hemorrhag...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelkar, Aditya, Gandhi, Poonam, Amoaku, Winfried, Kelkar, Jai, Kelkar, Shreekant, Raut, Priyanka, Shah, Rachana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2014
Materias:
Published online: July, 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130817/
https://www.ncbi.nlm.nih.gov/pubmed/25126075
http://dx.doi.org/10.1159/000365442
_version_ 1782330376218214400
author Kelkar, Aditya
Gandhi, Poonam
Amoaku, Winfried
Kelkar, Jai
Kelkar, Shreekant
Raut, Priyanka
Shah, Rachana
author_facet Kelkar, Aditya
Gandhi, Poonam
Amoaku, Winfried
Kelkar, Jai
Kelkar, Shreekant
Raut, Priyanka
Shah, Rachana
author_sort Kelkar, Aditya
collection PubMed
description We hereby report a case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy (CSC). Issues regarding safety and adverse effects of bevacizumab are discussed. To the best of our knowledge, this is the first reported case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal CSC.
format Online
Article
Text
id pubmed-4130817
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-41308172014-08-14 Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy Kelkar, Aditya Gandhi, Poonam Amoaku, Winfried Kelkar, Jai Kelkar, Shreekant Raut, Priyanka Shah, Rachana Case Rep Ophthalmol Published online: July, 2014 We hereby report a case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy (CSC). Issues regarding safety and adverse effects of bevacizumab are discussed. To the best of our knowledge, this is the first reported case of hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal CSC. S. Karger AG 2014-07-11 /pmc/articles/PMC4130817/ /pubmed/25126075 http://dx.doi.org/10.1159/000365442 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: July, 2014
Kelkar, Aditya
Gandhi, Poonam
Amoaku, Winfried
Kelkar, Jai
Kelkar, Shreekant
Raut, Priyanka
Shah, Rachana
Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy
title Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy
title_full Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy
title_fullStr Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy
title_full_unstemmed Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy
title_short Hemorrhagic Macular Infarction after Intravitreal Bevacizumab for Chronic Multifocal Central Serous Chorioretinopathy
title_sort hemorrhagic macular infarction after intravitreal bevacizumab for chronic multifocal central serous chorioretinopathy
topic Published online: July, 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130817/
https://www.ncbi.nlm.nih.gov/pubmed/25126075
http://dx.doi.org/10.1159/000365442
work_keys_str_mv AT kelkaraditya hemorrhagicmacularinfarctionafterintravitrealbevacizumabforchronicmultifocalcentralserouschorioretinopathy
AT gandhipoonam hemorrhagicmacularinfarctionafterintravitrealbevacizumabforchronicmultifocalcentralserouschorioretinopathy
AT amoakuwinfried hemorrhagicmacularinfarctionafterintravitrealbevacizumabforchronicmultifocalcentralserouschorioretinopathy
AT kelkarjai hemorrhagicmacularinfarctionafterintravitrealbevacizumabforchronicmultifocalcentralserouschorioretinopathy
AT kelkarshreekant hemorrhagicmacularinfarctionafterintravitrealbevacizumabforchronicmultifocalcentralserouschorioretinopathy
AT rautpriyanka hemorrhagicmacularinfarctionafterintravitrealbevacizumabforchronicmultifocalcentralserouschorioretinopathy
AT shahrachana hemorrhagicmacularinfarctionafterintravitrealbevacizumabforchronicmultifocalcentralserouschorioretinopathy

Ejemplares similares